Transglutaminase-2 Cross-Linking Inhibition Strategy

Target: TGM2 Composite Score: 0.639 Price: $0.64▲54.2% Citation Quality: Pending neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
🟢 Parkinson's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation 🔴 Alzheimer's Disease 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration
✓ All Quality Gates Passed
Quality Report Card click to collapse
B
Composite: 0.639
Top 40% of 1374 hypotheses
T1 Established
Multi-source converged and validated
T0 Axiom requires manual override only
B+ Mech. Plausibility 15% 0.75 Top 29%
B Evidence Strength 15% 0.60 Top 45%
B+ Novelty 12% 0.70 Top 47%
A Feasibility 12% 0.80 Top 21%
B+ Impact 12% 0.70 Top 42%
A Druggability 10% 0.85 Top 19%
B Safety Profile 8% 0.65 Top 29%
B+ Competition 6% 0.75 Top 30%
B+ Data Availability 5% 0.70 Top 31%
B+ Reproducibility 5% 0.75 Top 20%
Evidence
3 supporting | 3 opposing
Citation quality: 85%
Debates
1 session A+
Avg quality: 0.95
Convergence
1.00 A+ 30 related hypothesis share this target

From Analysis:

Protein aggregation cross-seeding across neurodegenerative diseases

What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative diseases?

→ View full analysis & debate transcript

Hypotheses from Same Analysis (6)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Glycosaminoglycan Template Disruption Approach
Score: 0.597 | Target: HSPG2
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.584 | Target: TREM2
Liquid-Liquid Phase Separation Modifier Therapy
Score: 0.551 | Target: G3BP1
HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor
Score: 0.544 | Target: DNAJB6
Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption
Score: 0.469 | Target: PHB2
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.465 | Target: TARDBP

→ View full analysis & all 7 hypotheses

Description

Transglutaminase-2 creates covalent cross-links between lysine and glutamine residues shared across tau, α-synuclein, and TDP-43, stabilizing heterologous aggregates. Selective TG2 inhibitors targeting the cross-seeding-specific substrate sites could disrupt mixed aggregate formation while preserving physiological TG2 functions.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["""Neuroinflammation
& Calcium Dysregulation"""] -->|"Ca2+ Influx"| B["TG2 Activation
(Transglutaminase-2)"] B -->|"Isopeptide Bond
Formation"| C["Tau Cross-Linking
& Aggregation"] B -->|"Protein Cross-Linking"| D["Abeta Oligomer
Stabilization"] B -->|"ECM Cross-Linking"| E["BBB Disruption
& Matrix Stiffening"] B -->|"NF-kappaB Activation"| F["Pro-inflammatory
Cytokine Cascade"] C --> G["Neurofibrillary
Tangle Formation"] D --> H["Amyloid Plaque
Stabilization"] E --> I["Peripheral Immune
Cell Infiltration"] F --> J["Chronic
Neuroinflammation"] G --> K["Neuronal Death
& Cognitive Decline"] H --> K I --> J J --> K L["""TG2 Inhibitor
Therapy"""] -->|"Selective Active-Site
Blockade"| M["TG2 Cross-Linking
Inhibition"] M -->|"Reduced Tau
Cross-Linking"| N["Prevented Tangle
Formation"] M -->|"Reduced Abeta
Stabilization"| O["Enhanced Abeta
Clearance"] M -->|"Preserved BBB
Integrity"| P["Reduced Immune
Infiltration"] M -->|"Suppressed NF-kappaB"| Q["Reduced
Neuroinflammation"] N --> R["Neuroprotection &
Cognitive Preservation"] O --> R P --> R Q --> R style A fill:#ff8a80,stroke:#d32f2f,color:#000 style L fill:#4fc3f7,stroke:#2196f3,color:#000 style R fill:#81c784,stroke:#4caf50,color:#000 style K fill:#ffab91,stroke:#e64a19,color:#000

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.75 (15%) Evidence 0.60 (15%) Novelty 0.70 (12%) Feasibility 0.80 (12%) Impact 0.70 (12%) Druggability 0.85 (10%) Safety 0.65 (8%) Competition 0.75 (6%) Data Avail. 0.70 (5%) Reproducible 0.75 (5%) KG Connect 0.74 (8%) 0.639 composite
6 citations 6 with PMID Validation: 85% 3 supporting / 3 opposing
For (3)
No supporting evidence
No opposing evidence
(3) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
6
MECH 6CLIN 0GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Transglutaminase-2 cross-links tau, α-synuclein, a…SupportingMECH----PMID:25242045-
TG2 activity is elevated in multiple neurodegenera…SupportingMECH----PMID:27784544-
Selective TG2 inhibitors reduce protein aggregatio…SupportingMECH----PMID:31756126-
TG2 activity can be protective in some neurodegene…OpposingMECH----PMID:27784544-
TG2 cross-linking often occurs after aggregate for…OpposingMECH----PMID:25242045-
Non-selective TG2 inhibition causes significant to…OpposingMECH----PMID:28847752-
Legacy Card View — expandable citation cards

Supporting Evidence 3

Transglutaminase-2 cross-links tau, α-synuclein, and TDP-43 in disease conditions
TG2 activity is elevated in multiple neurodegenerative diseases
Selective TG2 inhibitors reduce protein aggregation

Opposing Evidence 3

TG2 activity can be protective in some neurodegeneration contexts
TG2 cross-linking often occurs after aggregate formation, not during initial seeding
Non-selective TG2 inhibition causes significant toxicity
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-01 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration

Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor

Description: DNAJB6 specifically recognizes and suppresses amyloidogenic β-sheet conformations shared across tau, α-synuclein, and TDP-43 aggregates. Enhanced DNAJB6 expression or small molecule activators could provide broad-spectrum protection against cross-seeding by disrupting the common structural motifs that enable heterologous nucleation.

Target: DNAJB6 (DnaJ heat shock protein family member B6)

Supporting Evidence: DNAJB6 pote

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available.

Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor

Specific Weaknesses:

  • The evidence primarily focuses on polyglutamine aggregation, not tau, α-synuclein, or TDP-43
  • No direct evidence that DNAJB6 inhibits cross-seeding between different protein types
  • The cited PMIDs don't actually support cross-seeding inhibition claims
Counter-evidence:
  • DNAJB6 overexpression can actually promote tau aggregation in some contexts by interfering with normal proteostasis (PMID

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

PRACTICAL FEASIBILITY ASSESSMENT

Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor

Druggability: MODERATE-POOR

  • Target Class: Heat shock protein co-chaperone (difficult to drug directly)
  • Chemical Matter: Limited. No known direct DNAJB6 activators exist
  • Existing Tools:
  • HSP70 activators (YM-08, SW02) might indirectly enhance DNAJB6 function
  • Gene therapy vectors for DNAJB6 overexpression (preclinical only)
Competitive Landscape:
  • Direct competitors: None targeting DNAJB6 specifically
  • Adjacent space: Multiple HSP70/HSP90 programs (Orphazy

Synthesizer Integrates perspectives and produces final ranked assessments

Price History

0.250.500.75 created: market_dynamics (2026-04-02T21:38)score_update: market_dynamics (2026-04-02T21:38)score_update: market_dynamics (2026-04-02T21:43)score_update: market_dynamics (2026-04-02T23:19)debate: market_dynamics (2026-04-02T23:20)evidence: evidence_batch_update (2026-04-03T01:06)evidence: evidence_batch_update (2026-04-03T01:06)evidence: market_dynamics (2026-04-03T02:14)debate: market_dynamics (2026-04-03T03:00)evidence: market_dynamics (2026-04-03T03:10)debate: market_dynamics (2026-04-03T04:44)score_update: market_dynamics (2026-04-03T08:00)evidence: market_dynamics (2026-04-03T08:14)debate: market_dynamics (2026-04-03T09:14)evidence: evidence_batch_update (2026-04-04T09:08)evidence: evidence_batch_update (2026-04-13T02:18)evidence: evidence_batch_update (2026-04-13T02:18) 1.00 0.00 2026-04-022026-04-122026-04-22 Market PriceScoreevidencedebate 158 events
7d Trend
Stable
7d Momentum
▼ 1.3%
Volatility
Medium
0.0345
Events (7d)
6
⚡ Price Movement Log Recent 15 events
Event Price Change Source Time
📄 New Evidence $0.516 ▲ 1.8% evidence_batch_update 2026-04-13 02:18
📄 New Evidence $0.507 ▲ 3.9% evidence_batch_update 2026-04-13 02:18
Recalibrated $0.488 ▼ 1.2% 2026-04-10 15:58
Recalibrated $0.494 ▲ 1.4% 2026-04-10 15:53
Recalibrated $0.487 ▲ 0.3% 2026-04-08 18:39
Recalibrated $0.486 ▼ 0.7% 2026-04-04 16:38
Recalibrated $0.489 ▼ 1.9% 2026-04-04 16:02
📄 New Evidence $0.499 ▲ 2.2% evidence_batch_update 2026-04-04 09:08
Recalibrated $0.488 ▼ 27.6% 2026-04-03 23:46
💬 Debate Round $0.674 ▲ 2.0% market_dynamics 2026-04-03 09:14
📄 New Evidence $0.661 ▼ 1.8% market_dynamics 2026-04-03 08:14
📊 Score Update $0.673 ▲ 24.1% market_dynamics 2026-04-03 08:00
💬 Debate Round $0.542 ▼ 4.2% market_dynamics 2026-04-03 04:44
📄 New Evidence $0.566 ▼ 11.0% market_dynamics 2026-04-03 03:10
💬 Debate Round $0.636 ▲ 25.8% market_dynamics 2026-04-03 03:00

Clinical Trials (4) Relevance: 13%

2
Active
2
Completed
0
Total Enrolled
Phase II/III
Highest Phase
Cysteamine Bitartrate in Huntington's Disease (CYST-HD) Phase II/III
Completed · NCT02101957
Cysteamine for Neurodegenerative Disease Phase II
Completed · NCT03344601
Zampilimab (anti-TG2) in Celiac Disease Phase II
Recruiting · NCT04870866
Cross-Seeding Biomarkers in Neurodegenerative Disease Observational
Recruiting · NCT05538455

📚 Cited Papers (23)

[WALANT - Wide Awake Local Anaesthesia No Tourniquet: Complications in elective and acute traumatological Hand Surgery Procedures].
Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V... (2022) · PMID:35168268
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
deep_link
Engineering complex communities by directed evolution.
Nature ecology & evolution (2021) · PMID:33986540
9 figures
Extended Data Figure 1.
Extended Data Figure 1.
Non-additive function, costly function, and two empirically motivated functions. (A) Illustration of the different types of community function we have considered. In addition to th...
pmc_api
Extended Data Figure 2.
Extended Data Figure 2.
Alternative ecological scenarios with metabolic cross-feeding. Besides the rich medium without cross-feeding shown in the main text, we have included two other ecological scenarios...
pmc_api
Dietary Gluten and Neurodegeneration: A Case for Preclinical Studies.
International journal of molecular sciences (2020) · PMID:32751379
3 figures
Figure 1
Figure 1
Occludin (OCLN) protein expression is significantly decreased in duodenal epithelium of celiac macaques. All panels involve triple labels with OCLN ( green ), cytokeratin ( red ) a...
pmc_api
Figure 2
Figure 2
Immunopathology of central nervous system (CNS) disease in celiac disease patients and potential beneficial (treatment) role of phytocannabinoids as nutraceuticals to mitigate glut...
pmc_api
TGM2 and implications for human disease: role of alternative splicing.
Front Biosci (Landmark Ed) (2013) · PMID:23276939
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
deep_link
The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases.
International journal of molecular sciences (2024) · PMID:39769187
4 figures
Figure 1
Figure 1
Toxic protein biomarkers shared by specific and mixed pathology NDDs. The references supporting these relationships are cited in the main body of the text. The color of the individ...
pmc_api
Figure 2
Figure 2
Calcium–calmodulin mediated signal transduction in normal neurons ( top panel ) and neurodegeneration ( lower panel ). This essential signaling pathway mediates learning and memory...
pmc_api
Successful Nonoperative Treatment of Osteochondritis Dissecans of the Humeral Capitellum in a Young Baseball Player with Advanced Skeletal Maturity.
Progress in rehabilitation medicine (2021) · PMID:34825100
4 figures
Fig. 1.
Fig. 1.
Sonographic image of OCD of the humeral capitellum in the sagittal plane showing irregularity and discontinuity of the subchondral bone.
pmc_api
Fig. 2.
Fig. 2.
(A) Radiograph taken at the first examination showing an osteochondral lesion on the lateral side of the capitellum and new bone formation along the lateral side of capitellum (arr...
pmc_api
TGM2 and implications for human disease: role of alternative splicing.
Front Biosci (Landmark Ed) (2013) · PMID:23276939
No extracted figures yet
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
The Lancet. Oncology (2014) · PMID:25242045
No extracted figures yet
Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male.
Sexual medicine reviews (2015) · PMID:27784544
No extracted figures yet
The Combination of Alcohol and Cigarette Smoke Induces Endoplasmic Reticulum Stress and Cell Death in Pancreatic Acinar Cells.
Gastroenterology (2017) · PMID:28847752
No extracted figures yet
Sounds interesting: can sonification help us design new proteins?
Expert review of proteomics (2020) · PMID:31756126
No extracted figures yet
Urolithin A suppresses high glucose-induced neuronal amyloidogenesis by modulating TGM2-dependent ER-mitochondria contacts and calcium homeostasis.
Cell Death Differ (2021) · PMID:32704090
No extracted figures yet

📙 Related Wiki Pages (15)

EED geneTGM2 — Transglutaminase 2 geneAlibaba Tongyi Qianwen-Bio (Chinese Biomedical LLM ai_toolTGM2 Protein proteinTGM2 — Transglutaminase 2 geneNeurodegeneration diseaseAmyotrophic Lateral Sclerosis redirectTau Oligomers entityGenes indexEndoplasmic Reticulum Stress and Unfolded Protein mechanismBlood-Brain Barrier cellParkinson's Disease diseaseAmyotrophic Lateral Sclerosis (ALS) diseaseAlzheimer's Disease diseaseDopaminergic Neurons cell
࢐ Browse all wiki pages

📓 Linked Notebooks (4)

📓 SciDEX Analysis: 2026 04 01 Gap 9137255B
Computational notebook for SDA-2026-04-01-gap-9137255b
📓 Protein aggregation cross-seeding across neurodegenerative diseases — Analysis Notebook
Jupyter notebook for analysis SDA-2026-04-01-gap-9137255b: What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative diseases?
📓 Protein aggregation cross-seeding across neurodegenerative diseases — Rich Analysis
Enhanced notebook with gene expression, pathway enrichment, score heatmaps, and statistical analysis. What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative dise …
📓 Protein aggregation cross-seeding across neurodegenerative diseases
What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative diseases?
→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

Wiki Pages

EEDgeneTGM2 — Transglutaminase 2geneAlibaba Tongyi Qianwen-Bio (Chinese Biomedical LLMai_toolTGM2 ProteinproteinTGM2 — Transglutaminase 2geneNeurodegenerationdiseaseAmyotrophic Lateral SclerosisredirectTau OligomersentityGenesindexEndoplasmic Reticulum Stress and Unfolded Protein mechanismBlood-Brain BarriercellParkinson's DiseasediseaseAmyotrophic Lateral Sclerosis (ALS)diseaseAlzheimer's DiseasediseaseDopaminergic Neuronscell

Dependency Graph (1 upstream, 0 downstream)

Depends On
Low Complexity Domain Cross-Linking Inhibitionrefines (0.5)

Related Hypotheses

Low Complexity Domain Cross-Linking Inhibition
Score: 0.617 | neurodegeneration
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
Score: 0.990 | neurodegeneration
TREM2-Dependent Microglial Senescence Transition
Score: 0.950 | neurodegeneration
PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction
Score: 0.941 | neurodegeneration
Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction
Score: 0.933 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
2.0 years

🧪 Falsifiable Predictions (3)

3 total 0 confirmed 0 falsified
If hypothesis is true, intervention be most beneficial, positioning this strategy for prodromal or mild cognitive impairment stages rather than established dementia
pending conf: 0.60
Expected outcome: be most beneficial, positioning this strategy for prodromal or mild cognitive impairment stages rather than established dementia
Falsified by: Intervention fails to be most beneficial, positioning this strategy for prodromal or mild cognitive impairment stages rather than established dementia
If hypothesis is true, intervention enable non-invasive monitoring of enzyme activity in living brains
pending conf: 0.60
Expected outcome: enable non-invasive monitoring of enzyme activity in living brains
Falsified by: Intervention fails to enable non-invasive monitoring of enzyme activity in living brains
If hypothesis is true, intervention provide non-invasive measures of enzyme activity and inhibitor penetration
pending conf: 0.60
Expected outcome: provide non-invasive measures of enzyme activity and inhibitor penetration
Falsified by: Intervention fails to provide non-invasive measures of enzyme activity and inhibitor penetration

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 TGM2 — PDB 1KV3 Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Protein aggregation cross-seeding across neurodegenerative diseases

neurodegeneration | 2026-04-01 | completed

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)